Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (12): 11-20.doi: 10.6040/j.issn.1671-7554.0.2024.0181

• Clinical Pharmaceutical Research and Evaluation • Previous Articles    

Clinical efficacy and influencing factors of tigecycline in treatment of infectious diseases

FENG Xuqiang1,2, GAO Ping1, SUN Chao3, TAO Lin2,YAN Genquan1, LENG Bing1   

  1. 1. Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China;
    2. Department of Pharmacy, The Second Children and Women Healthcare of Jinan City, Jinan 271100, Shandong, China;
    3. Department of Clinical Pharmacy, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2024-12-09

PDF (PC)

39

Abstract: Objective To investigate the clinical efficacy and influencing factors of tigecycline in the treatment of infectious diseases. Methods A total of 746 medical records of patients treated with tigecycline in Shandong Provincial Hospital Affiliated to Shandong First Medical University during January 2017 and December 2020 were retrospectively collected, and the clinical data of patients were analyzed to evaluate the clinical efficacy and factors. Results This study included 726 valid cases. Respiratory infection(65.43%)and complicated intra-abdominal infection(cIAI)(27.13%)were the main infections. The clinical effective rate was 65.70%, and the incidence of adverse reactions was 4.68%. Logistic regression analysis showed that the risk factors for the failure of tigecycline treatment were malignant solid tumor(OR=1.931, 95%CI: 1.161-3.214, P=0.011), respiratory system infection(OR=1.704, 95%CI: 1.096-2.649, P=0.018), septic shock(OR=2.784, 95%CI: 1.766-4.389, P<0.001), mechanical ventilation(OR=1.809, 95%CI: 1.143-2.862, P=0.011)and continuous renal replacement therapy(CRRT)(OR=1.886, 95%CI: 1.136-3.129, P=0.014), while the protective factors were admission to ICU(OR=0.518, 95%CI: 0.309-0.870, P=0.013)and long duration(OR=0.952, 95%CI: 0.919-0.985, P=0.005). Conclusion Tigecycline is mainly used for the treatment of severe and complex infections caused by multidrug-resistant bacteria. Patients with malignant solid tumor, respiratory system infection, septic shock, mechanical ventilation and CRRT have higher risk of tigecycline treatment failure, which should be paid attention to during the treatment.

Key words: Bacterial infection, Tigecycline, Clinical efficacy, Influencing factors

CLC Number: 

  • R453.2
[1] Leng B, Yan GQ, Wang CC, et al. Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline[J]. J Glob Antimicrob Resist, 2021, 25: 315-322. doi:10.1016/j.jgar.2021.04.006.
[2] 刘心伟, 李登州, 胡玥, 等. 2020—2022年河南省某医院高毒力耐碳青霉烯类肺炎克雷伯菌分子流行病学特征研究[J]. 中华预防医学杂志, 2023, 57(8): 1222-1230. LIU Xinwei, LI Dengzhou, HU Yue, et al. Molecular epidemiological characterization of hypervirulent carbapenem-resistant Klebsiella pneumoniae in a hospital in Henan Province from 2020 to 2022[J]. Chinese Journal of Preventive Medicine, 2023, 57(8): 1222-1230.
[3] 隋东江, 张晓艳, 黄燕, 等. 多重耐药鲍曼不动杆菌肺部老年感染患者危险因素分析及替加环素治疗效果分析[J]. 中华保健医学杂志, 2022, 24(4): 280-283. SUI Dongjiang, ZHANG Xiaoyan, HUANG Yan, et al. Analysis of risk factors and therapeutic effect of tigecycline in elderly patients with pulmonary infection caused by multidrug-resistant Acinetobacter baumannii[J]. Chinese Journal of Health Care and Medicine, 2022, 24(4): 280-283.
[4] Mei HK, Yang TL, Wang J, et al. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2019, 74(12): 3423-3431.
[5] de Pascale G, Montini L, Pennisi MA, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Crit Care, 2014, 18(3): R90. doi:10.1186/cc13858.
[6] FDA. FDA Drug Safety Communication: Increased risk of death with Tygacil(tigecycline)compared to other antibiotics used to treat similar infections[EB/OL].(2010-09-01)[2024-02-01]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics.
[7] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志,2001,81(5):314-320.
[8] 《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则附件: 抗菌药物立题原则建议[J]. 中国临床药理学杂志, 2014, 30(9): 857-858.
[9] 国家药品监督管理局.个例药品不良反应收集和报告指导原则[EB/OL].国家药监局通告[2018] 第131号.(2018-12-19)[2024-02-01]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypggtg/ypqtggtg/20181221172901438.html.
[10] Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2011, 66(9): 1963-1971.
[11] 王凯歌, 谭芬, 彭红, 等. 替加环素治疗泛耐药鲍曼不动杆菌医院获得性肺炎的临床疗效及不良反应[J]. 中国感染控制杂志, 2016, 15(2): 97-101. WANG Kaige, TAN Fen, PENG Hong, et al. Clinical efficacy and adverse reactions of tigecycline in treatment of healthcareassociated pneumonia caused by extensively drug-resistant Acinetobacter baumannii[J]. Chinese Journal of Infection Control, 2016, 15(2): 97-101.
[12] Hasan MJ, Nizhu LN, Rabbani R. Bloodstream infection with pandrug-resistant Alcaligenes faecalis treated with double-dose of tigecycline[J]. IDCases, 2019, 18:e00600. doi: 10.1016/j.idcr.2019.e00600.
[13] 肖婷婷, 肖永红. 耐碳青霉烯类肠杆菌科细菌感染治疗策略研究进展[J]. 医药导报, 2018, 37(1): 1-5. XIAO Tingting, XIAO Yonghong. Treatment strategies for carbapenem-resistant Enterobacteriaceae infections[J]. Herald of Medicine, 2018, 37(1): 1-5.
[14] Ni WT, Yang DQ, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae[J]. J Antimicrob Chemother, 2021, 76(8): 2097-2105.
[15] Eckmann C, Heizmann W, Bodmann KF, et al. Tigecycline in the treatment of patients with necrotizing skin and soft tissue infections due to multiresistant bacteria[J]. Surg Infect, 2015, 16(5): 618-625.
[16] Solomkin J, Mullins CD, Quintana A, et al. Evaluation of tigecycline efficacy and post-discharge outcomes in a clinical practice population with complicated intra-abdominal infection: a propensity score-matched analysis[J]. Surg Infect(Larchmt), 2016, 17(4): 402-411.
[17] 贾雪冬, 王松, 王晓娟, 等. 替加环素治疗耐碳青霉烯类肺炎克雷伯菌肺炎(CRKP)的疗效和影响因素分析[J]. 中国医院药学杂志, 2019, 39(18): 1865-1868. JIA Xuedong, WANG Song, WANG Xiaojuan, et al. Efficacy and influencing factors of tigecycline in treatment of Carbapenem-Resistant Klebsiella Pneumonia(CRKP)infection[J]. Chinese Journal of Hospital Pharmacy, 2019, 39(18): 1865-1868.
[18] Liou BH, Lee YT, Kuo SC, et al. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure[J]. Antimicrob Agents Chemother, 2015, 59(6): 3637-3640.
[19] Liang CA, Lin YC, Lu PL, et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii[J]. Clin Microbiol Infect, 2018, 24(8): 908.
[20] Seifert H, Blondeau J, Lucaßen K, et al. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes(2016-2018)[J]. J Glob Antimicrob Resist, 2022, 31: 82-89. doi: 10.1016/j.jgar.2022.08.002.
[21] 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.
[22] Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, et al. Impact of tigecyclines MIC in the outcome of critically ill patients with carbapenemase-producing Klebsiella pneumoniae bacteraemia treated with tigecycline monotherapy-validation of 2019s EUCAST proposed breakpoint changes[J]. Antibiotics, 2020, 9(11): 828.
[23] Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline[J]. Int J Antimicrob Agents, 2005, 25(6): 523-529.
[24] Pedicini M, Barrenäs F, Clancy T, et al. Combining network modeling and gene expression microarray analysis to explore the dynamics of Th1 and Th2 cell regulation[J]. PLoS Comput Biol, 2010, 6(12): e1001032. doi:10.1317/journal.pcbi.1001032.
[25] 李慧敏, 王昆, 郝梦迪, 等. 老年恶性肿瘤患者医院感染的危险因素分析[J]. 医学信息, 2023, 36(4): 175-178. LI Huimin, WANG Kun, HAO Mengdi, et al. Analysis of risk factors for nosocomial infection in elderly patients with malignant tumor[J]. Journal of Medical Information, 2023, 36(4): 175-178.
[26] Cai XF, Yan HX, Zhang WJ, et al. Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone[J]. BMC Cancer, 2023, 23(1): 682.
[27] 柴艳芬, 刘艳存, 高玉雷. 脓毒性休克的液体复苏策略[J]. 实用休克杂志(中英文), 2020, 4(4): 193-196, 202. CHAI Yanfen, LIU Yancun, GAO Yulei. Fluid resuscitation strategy for septic shock[J]. Journal of Practical Shock, 2020, 4(4): 193-196, 202.
[28] 谭瑞娟, 王立丹, 贺平, 等. 重症胸部创伤术后机械通气患者肺部多重耐药菌感染病原菌分布及危险因素分析[J]. 中国医院药学杂志, 2022, 42(8): 840-843. TAN Ruijuan, WANG Lidan, HE Ping, et al. Analysis of pathogenic bacteria distribution and influencing factors of pulmonary multidrug-resistant bacterial infection of mechanically ventilated patients after severe chest trauma[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(8): 840-843.
[29] Li L, Li X, Xia YZ, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy[J]. Front Pharmacol, 2020, 11: 786. doi:10.3389/fphar.2020.00786.
[30] Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study[J]. Crit Care, 2018, 22(1): 341.
[31] 李杨. 替加环素治疗危重患者多重耐药菌感染的疗效研究[D]. 苏州: 苏州大学, 2015.
[32] Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens[J]. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113.
[33] Li J, Yang XH, Chen LD, et al. In vitro activity of various antibiotics in combination with tigecycline against Acinetobacter baumannii: a systematic review and meta-analysis[J]. Microb Drug Resist, 2017, 23(8): 982-993.
[34] 钟雪, 冯婉玉. 替加环素单药与联合方案治疗多重耐药菌感染疗效对比的系统评价[J]. 中国抗生素杂志, 2018, 43(2): 127-134. ZHONG Xue, FENG Wanyu. A systematic review on tigecycline-based combination treatment versus monotherapy for multidrug resistant infectious diseases[J]. Chinese Journal of Antibiotics, 2018, 43(2): 127-134.
[35] Zha L, Pan LL, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3): 1049-1064.
[36] Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections[J]. Clin Infect Dis, 2022, 74(12): 2089-2114.
[37] 临床常用四环素类药物合理应用多学科专家共识编写组. 临床常用四环素类药物合理应用多学科专家共识[J]. 中华医学杂志, 2023, 103(30): 2281-2296. Editing Group for Multidisciplinary expert consensus on the rational use of tetracyclines commonly used in clinical practice. Multidisciplinary expert consensus on the rational use of tetracyclines commonly used in clinical practice[J]. Natl Med J China, 2023, 103(30): 2281-2296.
[38] Chen ZH, Shi XY. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens[J]. Medicine, 2018, 97(38): e12467. doi:10.1097/MD.0000000000012467.
[1] SUN Xiaodan, YANG Chuang. Clinical efficacy of polymyxin B in treatment of patients infected with carbapenem resistant Gram-negative bacteria in intensive care unit [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 72-77.
[2] LIU Feng, MA Caixia, LI Chunyan, CHENG Haiying, JIN Leyu, LIU Zhong, LI Xuewen. Incidence and influencing factors of influenza-like illness among college students in Jinan during the influenza peak period in November 2023 [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 91-97.
[3] JING Rui, ZHANG Wenqian, DONG Hui, DONG Yiran, YU Shengnan, DUAN Yong, YAN Qin, ZHAO Chuanlu, LI Xiujun, WANG Weibing. Current status of tuberculosis prevention and control knowledge, attitude and practice and the influencing factors of behavior among freshmen in colleges and universities in Jinan, Shandong Province [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 101-107.
[4] YU Feiping, LI Xin, SI Mingshu, ZHANG Dan, SU Yonggang. Medical college students knowledge of the integrated elderly care and medical services, and their employment willingness to elderly care [J]. Journal of Shandong University (Health Sciences), 2024, 62(11): 105-114.
[5] LIU Fengqi, GAO Feng, XUE Caicai, QIAO Xiumei, WANG Jinhong. Influencing factors of PC12 cell injury induced by high glucose and the protective effects of catalpol [J]. Journal of Shandong University (Health Sciences), 2023, 61(7): 34-39.
[6] HAN Luyi, TIAN Xueying, GAO Qi, SHE Kaili, CAO Yunxian, WEI Shushu, Ding Shujun, LI Xiujun. MaxEnt modeling to analyze influencing factors of severe fever with thrombocytopenia syndrome and predict the potential distribution in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 103-110.
[7] ZHENG Liang, SUN Minghao, SHI Yuan, YU Shengnan, WANG Zhiqiang, LI Xiujun. Spatio-temporal distribution and influencing factors of hantavirus hemorrhagic fever with renal syndrome in Shandong Province, 2011—2019 [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 104-110.
[8] JIANG Lili, CHEN Peng, XU Xinyang, ZHANG Xiaorong, MENG Qiuyu, QI Dong, YANG Chuanjing, WU Qian. Glove perforation and its influencing factors in 141 cases of subgingival scaling [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 83-87.
[9] WANG Jiongjiong, WANG Guoyong, ZHU Xiaoyan, LI Ling, ZHANG Na, LIU Yunxia. Immediate antiretroviral treatment in 1,926 cases of HIV infection through homosexual transmission in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 100-105.
[10] XU Kai, HAN Chao, DING Shouluan, DING Xuan, XING Deguang, WANG Chengwei. Factors of preoperative rebleeding in 181 patients with poor-grade aneurysmal subarachnoid hemorrhage [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 97-101.
[11] XU Xiaofen, ZHU Xiao, MA Wei, LI Na. Influencing factors of cancer pain management disorder in 123 cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 119-124.
[12] HOU Runan, SHAO Di, QIN Tingting, SHANG Meimei, SHEN Yuzhen, SUN Xiaojie. Tobacco use status and influencing factors of cancer patients in shandong province [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 102-106.
[13] ZHAO Sibo, PENG Li, LING Hongxiang. Relationship between medical insurance participation and risk of suicide among rural elderly [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 113-118.
[14] HAN Xuan, SUN Xiubin, LIU Yi, WANG Shukang, LIU Jing, YUAN Zhongshang, ZHANG Tao, LI Xiujun, XUE Fuzhong, LIU Yunxia. Evaluation of learning satisfaction of preventive medicine students with Health Statistics [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 109-113.
[15] SU Yonggang, WANG Rui, YANG Tongwei. Influencing factors and preventive measures of elderly suicide from the perspective of Healthy China Initiative [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 8-13.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd